NGS-Based RNA-Sequencing Market By Product and Service , By Technology , By Application, By End User, and By Region - Trends, Analysis and Forecast till 2034

NGS-Based RNA-Sequencing Market accounted for USD 2.1 Billion in 2024 and is estimated to be USD 11.1 Billion by 2034 and is anticipated to register a CAGR of 18.10%.

Next-generation sequencing (NGS), also known as high-throughput sequencing, is the term used to describe a number of different modern sequencing technologies. The increasing focus on genetic studies and gene based therapeutic technologies is expected to boost the growth of the market in coming years. The massively parallel sequencing technology known as next-generation sequencing (NGS) has revolutionized the biological sciences. With its ultra-high throughput, scalability, and speed, NGS enables researchers to perform a wide variety of applications and study biological systems at a level never before possible.

The NGS-based RNA-sequencing market is driven by the driving factor such as reduced cost of genome sequencing, advancements in sequencing technology and next generation sequencing for cancer. The demand for NGS-based RNA-sequencing is rising due to various factors including technological advancements in RNA-sequencing products, benefits of RNA-sequencing as compared to microarray technology. In addition, rapid growth in research activities, growing amount of RNA-sequencing grants, and significant demand for precision medicine are expected to drive the demand in the target market. Moreover, the increase in the service provider companies have entered the market and they are offering next generation sequencing in cheaper cost. However, the global market is likely to face the restraining factors such as risks related to genetic data and high cost of NGS instruments market. The future trend that is likely to drive the global market growth is barcode scanning for long reads sequences. Dearth of skilled professionals and problems associated with storage of sequencing data restrain the target market growth. Nevertheless, government initiatives in population sequencing and emerging markets such as china & India offer significant growth opportunities for the target market growth.

The NGS-based RNA-sequencing market is segmented based on product and service, technology, application, end user and region.

Based on product and service, the NGS-based RNA-sequencing market is segmented into sample preparation products, sequencing platforms & consumables, sequencing services, and data analysis, storage, & management. The RNA sequencing platforms & consumables segment accounted for the largest share of the NGS based RNA sequencing market. This can be attributed to continuous technological advancements witnessed in the target market and the increasing availability of innovative & cost-effective sequencing platforms. Based on the technology, the target market is segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. Based on application, the global market is classified into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. Based on end user, the target market is bifurcated into research & academia, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users.

Based on the region the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts high revenue share to NGS-based RNA-sequencing market due to the government support through funds for genomics research. On the other hand, Asia Pacific is expected to create lucrative opportunity for this market. Rising government initiatives to offer better public health facilities and investing huge sum of money in advanced diagnostic approaches are the key factors stoking up the demand for NGS-based RNA-sequencing in this region. In addition, key players are also enthusiastic on investing in emerging economies in Asia Pacific.

NGS-Based RNA-Sequencing Market, By Product and Service:

• Sample Preparation Products
• Sequencing Platforms & Consumables
• Sequencing Services
•  Data Analysis, Storage, & Management

NGS-Based RNA-Sequencing Market, By Technology:

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing
• Nanopore Sequencing

NGS-Based RNA-Sequencing Market, By Application:

• Expression Profiling Analysis
• Small RNA Sequencing
• De Novo Transcriptome Assembly
• Variant Calling & Transcriptome Epigenetics

NGS-Based RNA-Sequencing Market, By End User:

• Research & Academia
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other End Users

NGS-Based RNA-Sequencing Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the global NGS-Based RNA-sequencing market involves Illumina, Thermo Fischer Scientific, Oxford Nanopore, Agilent Technologies, Inc., BGI, Perkinelmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Takara Bio Inc. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, in May 2019, BGI (china) and Genomiqa signed a services agreement for whole-genome sequencing on BGI’s DNBseqTM sequencing technology platform. Under this agreement, Genomiqa will utilize BGI’s iso15189 accredited laboratory sequencing facilities. In November 2018, Illumina acquired Pacific Biosciences, one of the leading provider of sequencing systems. This helped Illumina strengthen its sequencing product portfolio.

• Illumina
• Thermo Fischer Scientific
• Oxford Nanopore
• Agilent Technologies, Inc.
• BGI
• Perkinelmer Inc.
• QIAGEN
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Takara Bio Inc